Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462547 · ClinicalTrials.gov registry record · Phase 2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
A Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT06462547: Recruiting Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
NCT06462547 is a Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum that is actively recruiting participants, run by Inozyme Pharma. The registered enrollment target is 200 participants, below the 263-participant average among 4 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (24% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462547, a Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, is actively recruiting participants, sponsored by Inozyme Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Primary Outcome
Treatment-emergent AEs are defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.
Conditions Studied
Interventions
- DRUG INZ-701
Study Locations (5)
Other
- Necker-Enfants Malades Hospital - Paris
- Universitätsklinikum Hamburg-Eppendorf (UKE) - Hamburg
- VCTC - Oxford
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT06462547 shows while recruiting
NCT06462547 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 263-participant average among 4 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (24% lower).
The record links to 5 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which INZ-701 is the first listed.
NCT06462547 lists 5 locations in 3 states (Other, Minnesota, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06462547 about?
NCT06462547 is a clinical study titled "ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency". The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
What is the current status of trial NCT06462547?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-06-19. Estimated completion is 2030-12.
What conditions does trial NCT06462547 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Pseudoxanthoma Elasticum, Arterial Calcification, Autosomal Recessive Hypophosphatemic Rickets Type 2, Gene Mutations.
What interventions are being tested in trial NCT06462547?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT06462547?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462547 being conducted?
This trial has 5 study locations across Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
RECRUITING
-
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI